494 related articles for article (PubMed ID: 12131543)
21. Relation of left ventricular geometry and function to systemic hemodynamics in hypertension: the LIFE Study. Losartan Intervention For Endpoint Reduction in Hypertension Study.
Bella JN; Wachtell K; Palmieri V; Liebson PR; Gerdts E; Ylitalo A; Koren MJ; Pedersen OL; Rokkedal J; Dahlöf B; Roman MJ; Devereux RB
J Hypertens; 2001 Jan; 19(1):127-34. PubMed ID: 11204292
[TBL] [Abstract][Full Text] [Related]
22. Association of heart failure hospitalizations with combined electrocardiography and echocardiography criteria for left ventricular hypertrophy.
Gerdts E; Okin PM; Boman K; Wachtell K; Nieminen MS; Dahlöf B; Devereux RB
Am J Hypertens; 2012 Jun; 25(6):678-83. PubMed ID: 22456225
[TBL] [Abstract][Full Text] [Related]
23. Changes in electrocardiographic left ventricular hypertrophy and risk of major cardiovascular events in isolated systolic hypertension: the LIFE study.
Larstorp AC; Okin PM; Devereux RB; Olsen MH; Ibsen H; Dahlöf B; Kjeldsen SE; Wachtell K
J Hum Hypertens; 2011 Mar; 25(3):178-85. PubMed ID: 20505749
[TBL] [Abstract][Full Text] [Related]
24. Regression of electrocardiographic left ventricular hypertrophy is associated with less hospitalization for heart failure in hypertensive patients.
Okin PM; Devereux RB; Harris KE; Jern S; Kjeldsen SE; Julius S; Edelman JM; Dahlöf B;
Ann Intern Med; 2007 Sep; 147(5):311-9. PubMed ID: 17785486
[TBL] [Abstract][Full Text] [Related]
25. Effects of losartan and atenolol on left ventricular mass and neurohormonal profile in patients with essential hypertension and left ventricular hypertrophy.
Dahlof B; Zanchetti A; Diez J; Nicholls MG; Yu CM; Barrios V; Aurup P; Smith RD; Johansson M;
J Hypertens; 2002 Sep; 20(9):1855-64. PubMed ID: 12195129
[TBL] [Abstract][Full Text] [Related]
26. Characteristics of 9194 patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint Reduction in Hypertension.
Dahlöf B; Devereux RB; Julius S; Kjeldsen SE; Beevers G; de Faire U; Fyhrquist F; Hedner T; Ibsen H; Kristianson K; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H
Hypertension; 1998 Dec; 32(6):989-97. PubMed ID: 9856962
[TBL] [Abstract][Full Text] [Related]
27. Effects of angiotensin II receptor blockade-based therapy with losartan on left ventricular hypertrophy and geometry in previously treated hypertensive patients.
Cuspidi C; Meani S; Valerio C; Fusi V; Sala C; Maisaidi M; Zanchetti A
Blood Press; 2006; 15(2):107-15. PubMed ID: 16754274
[TBL] [Abstract][Full Text] [Related]
28. Impact of age on left ventricular hypertrophy regression during antihypertensive treatment with losartan or atenolol (the LIFE study).
Gerdts E; Roman MJ; Palmieri V; Wachtell K; Smith G; Nieminen MS; Dahlöf B; Devereux RB
J Hum Hypertens; 2004 Jun; 18(6):417-22. PubMed ID: 15103312
[TBL] [Abstract][Full Text] [Related]
29. Impact of diabetes mellitus on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcome during antihypertensive therapy: the Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study.
Okin PM; Devereux RB; Gerdts E; Snapinn SM; Harris KE; Jern S; Kjeldsen SE; Julius S; Edelman JM; Lindholm LH; Dahlöf B;
Circulation; 2006 Mar; 113(12):1588-96. PubMed ID: 16534012
[TBL] [Abstract][Full Text] [Related]
30. In-treatment resolution or absence of electrocardiographic left ventricular hypertrophy is associated with decreased incidence of new-onset diabetes mellitus in hypertensive patients: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) Study.
Okin PM; Devereux RB; Harris KE; Jern S; Kjeldsen SE; Lindholm LH; Dahlöf B;
Hypertension; 2007 Nov; 50(5):984-90. PubMed ID: 17893425
[TBL] [Abstract][Full Text] [Related]
31. Left ventricular filling patterns in patients with systemic hypertension and left ventricular hypertrophy (the LIFE study). Losartan Intervention For Endpoint.
Wachtell K; Smith G; Gerdts E; Dahlöf B; Nieminen MS; Papademetriou V; Bella JN; Ibsen H; Rokkedal J; Devereux RB
Am J Cardiol; 2000 Feb; 85(4):466-72. PubMed ID: 10728952
[TBL] [Abstract][Full Text] [Related]
32. Relationship of left atrial enlargement to persistence or development of ECG left ventricular hypertrophy in hypertensive patients: implications for the development of new atrial fibrillation.
Okin PM; Gerdts E; Wachtell K; Oikarinen L; Nieminen MS; Dahlöf B; Devereux RB
J Hypertens; 2010 Jul; 28(7):1534-40. PubMed ID: 20589977
[TBL] [Abstract][Full Text] [Related]
33. Electrocardiographic strain pattern and prediction of new-onset congestive heart failure in hypertensive patients: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study.
Okin PM; Devereux RB; Nieminen MS; Jern S; Oikarinen L; Viitasalo M; Toivonen L; Kjeldsen SE; Dahlöf B;
Circulation; 2006 Jan; 113(1):67-73. PubMed ID: 16365195
[TBL] [Abstract][Full Text] [Related]
34. Echocardiographic Left Ventricular Reverse Remodeling After 18 Months of Antihypertensive Treatment in Stage I Hypertension. Results From the Prever-Treatment Study.
Bertoluci C; Foppa M; Santos ABS; Branchi TV; Fuchs SC; Fuchs FD
Am J Hypertens; 2018 Feb; 31(3):321-328. PubMed ID: 29036504
[TBL] [Abstract][Full Text] [Related]
35. Incidence of atrial fibrillation in relation to changing heart rate over time in hypertensive patients: the LIFE study.
Okin PM; Wachtell K; Kjeldsen SE; Julius S; Lindholm LH; Dahlöf B; Hille DA; Nieminen MS; Edelman JM; Devereux RB
Circ Arrhythm Electrophysiol; 2008 Dec; 1(5):337-43. PubMed ID: 19808428
[TBL] [Abstract][Full Text] [Related]
36. Prognostic significance of left ventricular mass change during treatment of hypertension.
Devereux RB; Wachtell K; Gerdts E; Boman K; Nieminen MS; Papademetriou V; Rokkedal J; Harris K; Aurup P; Dahlöf B
JAMA; 2004 Nov; 292(19):2350-6. PubMed ID: 15547162
[TBL] [Abstract][Full Text] [Related]
37. Electrocardiographic characteristics and metabolic risk factors associated with inappropriately high left ventricular mass in patients with electrocardiographic left ventricular hypertrophy: the LIFE Study.
Palmieri V; Okin PM; de Simone G; Bella JN; Wachtell K; Gerdts E; Boman K; Nieminen MS; Dahlöf B; Devereux RB
J Hypertens; 2007 May; 25(5):1079-85. PubMed ID: 17414673
[TBL] [Abstract][Full Text] [Related]
38. Impact of achieved systolic blood pressure on renal function in hypertensive patients.
Okin PM; Kjeldsen SE; Devereux RB
Eur Heart J Qual Care Clin Outcomes; 2016 Oct; 2(4):271-276. PubMed ID: 29474712
[TBL] [Abstract][Full Text] [Related]
39. Cornell product in an electrocardiogram is related to reduced LV regional wall motion.
Ishikawa J; Yamanaka Y; Watanabe S; Toba A; Harada K
Hypertens Res; 2019 Apr; 42(4):541-548. PubMed ID: 30542082
[TBL] [Abstract][Full Text] [Related]
40. Association of pulse pressure with new-onset atrial fibrillation in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint (LIFE) reduction in hypertension study.
Larstorp AC; Ariansen I; Gjesdal K; Olsen MH; Ibsen H; Devereux RB; Okin PM; Dahlöf B; Kjeldsen SE; Wachtell K
Hypertension; 2012 Aug; 60(2):347-53. PubMed ID: 22753219
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
